Pfizer has made a $25 million equity investment in Caribou Biosciences, Inc., a clinical-stage CRISPR genome-editing biopharmaceutical company.
Caribou will use the investment to advance CB-011, an immune cloaked allogeneic CAR-T cell therapy currently being evaluated in the CaMMouflage Phase 1 trial in patients with relapsed or refractory multiple myeloma (r/r MM). Caribou will maintain full ownership and control of its pipeline of allogeneic CAR-T and CAR-NK cell therapies.
